Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
Authors' reply
EDITOR
Roderick and Cox's work shows that it is feasible to identify
patients with atrial fibrillation in clinical practice, which confirms
the suggestions from our data. They say, however, that only a small
proportion of those detected would be eligible for and would accept
warfarin treatment. Their eligibility estimates are considerably lower
than our own,1 and we suspect that this difference partly
reflects the effect of using different eligibility criteria, which we
have noted previously.2 Patients' understanding of the
risks and benefits of treatment and their view of the possible outcomes
are important determinants of the decision to treat and may also
explain some of the differences between our estimates. Further work is
required into methods for eliciting patients' preferences and
incorporating them into the choice of treatment and into clear
guidelines on the selection of patients for treatment.
We disagree with Fitzmaurice's assertion that the treatment
Read all Rapid Responses